Progressive supranuclear palsy (PSP) affects persons in their late 60s to 70s, because of the shrinkage of the upper ...

FNP-223, previously known as ASN90, is a reversible and substrate-competitive O-GlcNAcase enzyme inhibitor. The oral investigational drug is expected to rapidly increase O-GlcNAcylated tau proteins, ...

Background Progressive supranuclear palsy and Parkinson's disease have characteristic clinical and neuropathologic profiles, but also share overlapping clinical features. This study aimed to ...

Progressive supranuclear palsy (PSP) is characterized by progressive postural instability with falls, pseudobulbar palsy, axial parkinsonism, supranuclear vertical gaze palsy, ...

“When she would fall in public, people just assumed she was drunk,” said Glenn. “One time she fell backwards on the steps and ...

So, let’s talk about faith. I’m no rabbi or scholar, and I’m not trying to write a religious work. But putting my thoughts ...

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens ACCESS Newswire. April 28, 2025 9:05 AM.

When progressive supranuclear palsy (PSP), a rare neurodegenerative disorder, started affecting his movement, his wife and ...

References: Ferrer receives FDA Fast Track designation for FNP-223 in progressive supranuclear palsy (PSP). News release. Ferrer. June 17, 2025.

LONDON, GB / ACCESS Newswire / April 28, 2025 / The Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan ...